Curation CHNG3 MIR7-2
12 + 1.5 = 13.5 / 18
Genetic evidence
Total: 12
Category | Type | Citation | Score | Details |
|---|---|---|---|---|
Singular Evidence | Probands | 6 | STR3 or STR4* variants in the 15q TTTG STR were identified in 12 unrelated RTSH families; all 76 phenotypically assessed affected participants were heterozygous for STRmut, with 6 additional STRmut carriers whose pretreatment thyroid phenotype could not be assessed. | |
Collective Evidence | Segregation | 1.5 | Linkage analysis in family A identified a chr15q26.1 critical interval overlapping the TTTG STR (GRCh38 chr15:86,206,051-89,412,131; maximum LOD score 4.8), with the (TTTG)3 allele tracking with thyroid abnormalities in the pedigree. | |
Statistics | Case-control data | 6 | In a congenital hypothyroidism cohort, (TTTG)3/SNV variants were found in 137/989 cases (13.9%) versus 3/38,722 Japanese population controls (P<1e-300); an independent MNG cohort also showed enrichment (3/33 cases; P<1.2e-8 versus controls). |
Experimental evidence
Total: 1.5
Category | Type | Citation | Score | Details |
|---|---|---|---|---|
Function | Regulatory impact | 0.5 | Locus-specific regulatory evidence: snATAC-seq placed the (TTTG)4 region in thyroid-selective open chromatin, and luciferase assays in FRTL-5 and HEK293 cells showed WT repressor activity that was attenuated by (TTTG)3/SNV variants. | |
Functional Alteration | Patient cells | 1 | Patient-derived thyroid tissue from an adult (TTTG)3 carrier with MNG showed benign nodular pathology, heterogeneous follicle size, increased resorptive vacuoles, and thyroglobulin staining. |